Regeneron Pharmaceuticals Investor Presentation — August 2022

Document content

Regeneron -Internal Use Only

Regeneron Corporate Presentation

A u g u s t 2 0 2 2

This non -promotional presentation is intended for the investor audience and contains investigational data as well as forward -looking statements; actual results may vary

materiallyRegeneron -Internal Use Only

2This presentation includes forward -looking statements thatinvolve risks anduncertainties relating tofuture events andthefuture performance ofRegeneron Pharmaceuticals, Inc.(“Regeneron ”orthe“Company ”),andactual

events orresults may differ materially from these forward -looking statements .Words such as“anticipate, ”“expect, ”“intend, ”“plan, ”“believe, ”“seek, ”“estimate, ”variations ofsuch words, andsimilar expressions areintended to

identify such forward -looking statements, although notallforward -looking statements contain these identifying words .These statements concern, andthese risks anduncertainties include, among others, theimpact ofSARS -

CoV-2(thevirus thathascaused theCOVID -19pandemic) onRegeneron's business anditsemployees, collaborators, andsuppliers andother third parties onwhich Regeneron relies, Regeneron's anditscollaborators ’ability

tocontinue toconduct research andclinical programs, Regeneron's ability tomanage itssupply chain, netproduct sales ofproducts marketed orotherwise commercialized byRegeneron and/or itscollaborators orlicensees

(collectively, ”Regeneron ’sProducts “),andtheglobal economy ;thenature, timing, andpossible success andtherapeutic applications ofRegeneron ’sProducts andproduct candidates being developed byRegeneron and/or its

collaborators orlicensees (collectively, “Regeneron ’sProduct Candidates ”)andresearch andclinical programs now underway orplanned, including without limitation EYLEA®(aflibercept) Injection, Dupixent®(dupilumab),

Libtayo®(cemiplimab), Praluent®(alirocumab), Kevzara®(sarilumab), Evkeeza®(evinacumab ),Inmazeb®(atoltivimab ,maftivimab ,and odesivimab -ebgn ),REGEN -COV®(casirivimab and imdevimab ),aflibercept 8mg,

fasinumab, pozelimab ,odronextamab, itepekimab ,fianlimab, REGN 5458 ,REGN 5713 -5714 -5715 ,REGN 1908 -1909 ,Regeneron ’sanditscollaborators ’other oncology programs (including itscostimulatory bispecific portfolio),

Regeneron ’sanditscollaborators ’earlier -stage programs, andtheuseofhuman genetics inRegeneron ’sresearch programs ;safety issues resulting from theadministration ofRegeneron ’sProducts andRegeneron ’sProduct

Candidates inpatients, including serious complications orside effects inconnection with theuseofRegeneron ’sProducts andRegeneron ’sProduct Candidates inclinical trials ;thelikelihood, timing, andscope ofpossible

regulatory approval andcommercial launch ofRegeneron ’sProduct Candidates andnew indications forRegeneron ’sProducts, including without limitation those listed above ;thelikelihood andtiming ofachieving anyofthe